Abstract:Background: The survival rate of osteosarcoma therapy still lags behind overall cancer therapies due to the intrinsic or acquired drug resistance. Developing novel drug delivery systems that may overcome drug resistance would greatly facilitate osteosarcoma therapy. Methods: Poly(ethylene glycol) (PEG)-sheddable reduction-sensitive polyurethane (SS-PU-SS-PEG) was synthesized using a disulfide-containing polycaprolactone diol as the hydrophobic block and a cystamine-functionalized PEG as the hydrophilic block. SS-PU-SS-PEG micelles were then prepared to load the anti-tumor drug Doxorubicin (DOX) in order to achieve triggered intracellular drug delivery to improve the efficacy of osteosarcoma therapy. Results: When DOX was used as a model drug, the drug-loaded SS-PU-SS-PEG micelles were about 82 similar to 94 nm in diameter and exhibited good stability in phosphate buffer saline (PBS). The micelles could release about 80% DOX in a quantitative fashion within 5 hours under a reductive environment. The intracellular drug release of DOXloaded SS-PU-SS-PEG micelles increased upon incubation with Saos-2 cells in vitro. The micelles had good biocompatibility. In vitro, DOX-loaded SS-PU-SS-PEG micelles showed significant antitumor activity toward Saos-2 cells, which was close to that of free DOX. In vivo, DOX-loaded SS-PU-SS-PEG micelles exhibited better antitumor activity than free DOX. Conclusion: Findings from this study suggest that the SS-PU-SS-PEG micelles could achieve well-controlled triggered drug release in a reduction environment and could therefore improve the antitumor efficacy of osteosarcoma therapies. Translation potential of this article: In this study we developed PEG-sheddable reduction-sensitive polyurethane micelles (SS-PU-SS-PEG), which were able to achieve well-controlled triggered release of anti-tumor drug Doxorubicin (DOX) in an intracellular reduction environment. DOX-loaded SS-PU-SS-PEG micelles markedly improved the antitumor efficacy in a Saos-2 cells-bearing xenograft tumor model. Therefore, such micelles might be used as a novel drug delivery system for osteosarcoma treatment.

Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma

Targeted osteosarcoma chemotherapy using RGD peptide-installed doxorubicin-loaded biodegradable polymeric micelle

Bio-inspired Cisplatin Nanocarriers for Osteosarcoma Treatment.

Reduction-responsive Polypeptide Nanomedicines Significantly Inhibit Progression of Orthotopic Osteosarcoma.

Synergistic treatment of osteosarcoma with biomimetic nanoparticles transporting doxorubicin and siRNA

Poly(ethylene Glycol)-Sheddable Reduction-Sensitive Polyurethane Micelles for Triggered Intracellular Drug Delivery for Osteosarcoma Treatment

Tumor Microenvironment-Responsive Hyaluronate-Calcium Carbonate Hybrid Nanoparticle Enables Effective Chemotherapy for Primary and Advanced Osteosarcomas

Dual peptide-engineered and gadolinium-doped polydopamine particles as targeted nanotheranostics for the treatment of osteosarcoma and related osteolysis

Self‐Stabilized Hyaluronate Nanogel for Intracellular Codelivery of Doxorubicin and Cisplatin to Osteosarcoma

Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy

A bone-targeting permeable nanomicelle acting as an icebreaker for enhancing chemotherapy of osteosarcoma

Hybrid Cell Membrane-Functionalized Biomimetic Nanoparticles for Targeted Therapy of Osteosarcoma

Novel Nano-Capsule for Targeted Drug Delivery and Real-Time Therapeutic Monitoring in Osteosarcoma Treatment

Biodegradable Combinatorial Drug Loaded Ph-Sensitive Liposomes for Enhanced Osteosarcoma Therapeutics

Enhancing Osteosarcoma Killing and CT Imaging Using Ultrahigh Drug Loading and NIR-Responsive Bismuth Sulfide@Mesoporous Silica Nanoparticles

Doxorubicin-Loaded Tumor-Targeting Peptide-Decorated Polypeptide Nanoparticles for Treating Primary Orthotopic Colon Cancer

Sarcoma-Targeting Peptide-Decorated Polypeptide Nanogel Intracellularly Delivers Shikonin for Upregulated Osteosarcoma Necroptosis and Diminished Pulmonary Metastasis

Photodynamic-therapy and Chemotherapy of TPBC-PEG Nanoplatform Encapsulated Triptolide Synergistically Inhibit Primary Osteosarcoma Growth and Pulmonary Metastasis by Activating HIPPO Signaling

Recent Advances of Drug Delivery Nanocarriers in Osteosarcoma Treatment

Hyaluronate-Based Self-Stabilized Nanoparticles for Immunosuppression Reversion and Immunochemotherapy in Osteosarcoma Treatment

Targeted delivery of PD‐L1‐derived phosphorylation‐mimicking peptides by engineered biomimetic nanovesicles to enhance osteosarcoma treatment